B6;129S4-Slc22a6tm1.1(cre/ERT2)Amat/H
| Status | Available to order |
| EMMA ID | EM:10363 |
| International strain name | B6;129S4-Slc22a6tm1.1(cre/ERT2)Amat/H |
| Alternative name | Slc22a6-CreERT2 |
| Strain type | Targeted Mutant Strains : Knock-in |
| Allele/Transgene symbol | Slc22a6tm1.1(cre/ERT2)Amat, |
| Gene/Transgene symbol | Slc22a6 |
Information from provider
| Provider | Athena Matakidou |
| Provider affiliation | University of Cambridge CRUK Cambridge Institute |
| Genetic information | The CreERT2 gene was inserted at the endogenous ATG start site of the mouse Slc22a6 gene. This strain expresses the CreERT2 recombinase (tamoxifen-inducible) in Slc22a6 positive epithelia of proximal renal tubules. |
| Phenotypic information | Heterozygous and homozygous Slc22a6-CreERT2 mice are viable and display no discernible phenotype. Upon administration of tamoxifen recombinase activity is induced specifically in the epithelia of proximal renal tubules. |
| References | None available |
| Homozygous fertile | yes |
| Homozygous viable | yes |
| Homozygous matings required | no |
| Immunocompromised | no |
Information from EMMA
| Archiving centre | Mary Lyon Centre at MRC Harwell, Oxford, United Kingdom |